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Central blood pressure (BP) has been suggested to be a better predictor of cardiovascular 
disease risk than brachial BP. Given that central BP and arterial waveform are both influenced 
by insulin resistance, major initiators of insulin resistance—such as serum free fatty acid 
(FFA)—are suspected of potentially being involved in central hemodynamics. To confirm 
that insulin signaling is an important modulator of central hemodynamics, we investigated 
this hypothesis in a large-scale general population. Brachial BP and radial arterial waveform 
were measured simultaneously in 9,393 middle-aged to elderly individuals. The augmentation 
index (AIx) was calculated from the radial waveform as the ratio of the height of the late 
systolic peak to that of the first peak. Central systolic BP was defined as the absolute pressure 
of the late systolic peak of the waveform. Differences in central and brachial pulse pressure 
(PP) were considered to represent PP amplification. PP amplification differed significantly 
among serum FFA level quartiles (Q1, 7.8±5.3; Q2, 8.6±5.0; Q3, 9.3±5.7; Q4, 10.3±6.1 
mmHg, P<0.001), and the maximum difference in combination with diabetes status was 4.9 
mmHg. Multivariate analysis adjusted for major covariates indicated that higher serum FFA 
was an independent determinant for higher PP amplification (β=0.145, P<0.001) and lower 
AIx (β=-0.122, P<0.001) and central systolic BP (β=-0.044, P<0.001), while the association 
between FFA and PP amplification significantly decreased (β=0.022, P<0.001) after further 
adjustment for AIx. Serum FFA is an overlooked factor favorably influencing central 








Hypertension is a leading cause of cardiovascular disease, with brachial blood pressure (BP) 
being a standard measure in the assessment of arterial pressure load. However, central BP 
estimated from the radial arterial waveform has recently been suggested to be more closely 
associated with cardiovascular outcomes than brachial BP [1-3]. In addition to these 
epidemiological findings, clinical studies from several groups [4-6] and our own [7] have 
suggested that antihypertensive drugs might exert different effects on arterial waveform and 
central BP, possibly resulting in different cardiovascular outcomes. The Conduit Artery 
Function Evaluation sub-study [4] of the Anglo-Scandinavian Cardiac Outcomes Trial 
demonstrated that calcium-channel blockers were superior to β-blockers for reducing 
cardiovascular events. This effect was presumably due to the central systolic BP (SBP) being 
lower in the calcium-channel blocker treatment arm, while no class-specific effects were 
observed regarding brachial SBP. The apparent influence of central BP on cardiac outcomes 
highlights the importance of identifying factors that might affect central BP levels.  
Several factors have been reported to influence central BP levels by altering the arterial 
pressure waveform [8], a composite waveform of the forward pressure wave generated by 
cardiac ejection and the backward pressure wave reflected at peripheral sites. Arterial 
stiffness causes the early return of reflection pressure waves from peripheral sites and thus 
increases overlaps between forward and reflection pressure waves at the aorta, which increase 
central SBP. Other factors also influence arterial waveform, such as tall stature greatly 
decreasing the overlap of the two waveforms by delaying the arrival of the reflection pressure 




Curiously, type 2 diabetes and insulin resistance have been favorably associated with 
central hemodynamics. Several groups [9, 10] and our own [11] have shown that individuals 
with type 2 diabetes had relatively low central SBP, despite the well-established pathogenicity 
of diabetes for arterial stiffness and cardiovascular diseases. Although the mechanisms behind 
this paradoxical relationship are unclear, a possible explanation is reduced magnitude of the 
reflection pressure wave [12] due to a stiffer aortic artery and consequently larger penetration 
of pulsatile energy into the microcirculation [13, 14]. Insulin-mediated vasoconstriction under 
insulin-resistant conditions [15] might also be involved in the increased transmission of 
pulsatile energy.  
Free fatty acid (FFA) is a major initiator of insulin resistance [15, 16]. FFA blocks 
insulin signaling via phosphorylation of insulin receptor substrate 1, which inhibits 
translocation of glucose transporter to the cell membrane and reduces glucose uptake [15]. 
Further, FFA has been shown to reduce endothelium-dependent vasodilation by decreasing 
endothelial nitric oxide (NO) production [14]. Given these molecular bases of FFA in 
initiation of insulin resistance, we hypothesized that serum FFA levels might also be 
associated with central hemodynamics. Proving our hypothesis would further support the 
involvement of insulin signaling in central hemodynamic control, and would help to further 
understand the basis of paradoxical relationship between insulin resistance and better central 
hemodynamic profile. 
Here, we investigated our hypothesis using a dataset from the Nagahama Prospective 
Cohort for Comprehensive Human Bioscience (the Nagahama Study), a large-scale 






Study subjects were 9,393 apparently healthy middle-aged to elderly citizens who had 
participated in the Nagahama Study. This study cohort was recruited from 2008 to 2010 from 
the general population of Nagahama City, a largely sub-urban city of 125,000 inhabitants in 
central Japan. Community residents aged 30 to 74 years, living independently and with no 
physical impairment or dysfunction, were recruited. Of 9,804 total subjects, those meeting 
any of the following conditions were excluded from this study: history of symptomatic 
cardiovascular diseases (n=266), taking insulin therapy (n=22), unsuccessful assessment of 
clinical parameters required for this study (n=80), and pregnant women (n=43).  
Of the 9,393 subjects remaining after exclusion, individuals with available fasting blood 
specimens (>11 h) were used as the study panel (n=4,322), while those with peripheral blood 
samples drawn within 10 h of their last meal were used as the replication panel (n=5,071).  
All study procedures were approved by the ethics committee of Kyoto University 
Graduate School of Medicine and the Nagahama Municipal Review Board. Written informed 
consent was obtained from all participants.  
 
BP measurement 
Radial arterial waveform, brachial BP, and HR were measured simultaneously 
(HEM-9000AI; Omron Healthcare, Kyoto, Japan) after 5 min resting in the sitting position. 
Briefly, brachial BP was measured at the right upper arm using a cuff-oscillometric device, 
and the radial arterial waveform was simultaneously obtained from the left wrist using a 
multi-element tonometry sensor. The augmentation index (AIx) was calculated from the radial 
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arterial waveform as the ratio of the height of the late systolic peak (SBP2) to the first systolic 
peak. The absolute pressure of SBP2 obtained by calibrating the first systolic peak with 
brachial SBP was considered to represent the central SBP. Pulse pressure (PP) amplification 
was calculated by subtracting central PP from brachial PP and expressed in absolute values 
(mmHg). Measurements were taken twice, and the mean value of these measurements was 
used in analysis. The validity of SBP2 in estimating central SBP has been demonstrated by 
invasive simultaneous measurement of the ascending aorta and radial artery pressure [17, 18]. 
We also previously reported that radial SBP2 was closely related to the central SBP calculated 
by the widely used generalized transfer function [19]. Mean BP (MBP) was calculated using 
the following formula: MBP=DBP + (SBP − DBP)/3. 
 
Clinical parameters 
Basic clinical parameters were measured at the baseline examination of the Nagahama cohort 
study. Serum FFA levels were quantified using an enzymatic assay (NEFA-HR; Wako Pure 
Chemical Industries, Ltd., Osaka, Japan). Intra- and inter-assay coefficients of variation in 
FFA measurements were 1.42% and 1.79%, respectively. Homeostasis model assessment of 
insulin resistance (HOMA-IR) was calculated as an index of insulin resistance using the 
following formula: [insulin (IU/l) × glucose (mg/dl)]/405.  
 
Assessment of arterial stiffness 
Arterial stiffness was assessed by pulse wave velocity (PWV) measured between the brachia 
and ankle (baPWV). Briefly, cuffs were applied to both brachia and ankles, and blood 
pressure was measured simultaneously in the supine position using a cuff-oscillometric device 
7 
 
(Vasera-1500; Fukuda Denshi, Tokyo, Japan). Pulse volume waveforms were also recorded 
simultaneously using a plethysmographic sensor connected to the cuffs. The baPWV was 
calculated from the time interval between the wave fronts of the brachial and ankle 
waveforms and the path length from the brachia to ankle (0.597 × height + 14.4014) [20]. The 
co-linearity of baPWV with a carotid-to-femoral PWV, a standard measure of arterial 
stiffness, has been previously reported [21]. 
 
Statistical analysis 
Quartile of PP amplification and serum FFA level was calculated for each sex and then 
combined to avoid potential sex differences. Differences in numeric parameters among 
subgroups were assessed by analysis of variance, while the frequency of differences among 
subgroups was evaluated using a chi-squared test. Factors independently associated with PP 
amplification and AIx were assessed by multiple linear regression analysis. Statistical 
analysis was performed using JMP 9.0.3 software (SAS Institute, Cary, NC, USA). A p-value 
of less than 0.05 indicated statistical significance.  
 
RESULTS 
Clinical characteristics of study subjects are summarized in Table 1. Plasma levels of 
triglycerides, insulin, and FFA were slightly higher in the replication panel than in the study 
panel (P<0.001), while no marked differences were observed for other parameters.  
Table 2 shows the differences in metabolic parameters among quartiles of PP 
amplification. Subjects with larger PP amplification were markedly younger and taller and 
had faster HR than those with less amplification. Although several clinical parameters 
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significantly differed among quartiles in crude analysis, parameters for insulin resistance, 
including FFA levels, remained significant even after adjustment for major covariates.  
As a whole, women had significantly higher FFA levels than men (Figure 1). Older 
age (r=0.087, P<0.001), lower BMI (r=-0.084, P<0.001), increased HDL (r=0.190, P<0.001) 
and total cholesterol levels (r=0.085, P<0.001), and higher brachial SBP (r=0.057, P<0.001) 
had a significant but weak association with serum FFA levels (Tables S1 and S2). PP 
amplification markedly increased with FFA quartile (Figure 2), although both brachial and 
central SBP also showed linear association with FFA levels (Figure S1). In combined analysis 
with diabetes status (Figure 2C), differences in PP amplification between the highest (diabetic 
individuals with highest FFA quartile) and lowest (non-diabetic controls with lowest FFA 
quartile) subgroups reached approximately 4.9 mmHg. In contrast, AIx exhibited an inverse 
association with FFA quartile (Figure 2D), while baPWV was positively associated with FFA 
quartile (Figure 2E).  
Table 3 summarizes the results of multiple regression analysis for central 
hemodynamic parameters. Results indicated that serum FFA level was an independent 
positive determinant for PP amplification (Model 1). Given that FFA was also strongly and 
inversely associated with AIx, we further adjusted AIx in the regression analysis (Model 2). 
Although the association between serum FFA and PP amplification remained significant, the 
regression coefficient of FFA substantially decreased. Lower AIx might therefore be involved 
in the relationship between elevated serum FFA levels and elevated PP amplification. Further, 
FFA overtook the positive association between plasma insulin level and AIx (Models 3 and 4). 
Results of these regression analyses indicated that serum FFA levels rather than plasma 
insulin concentration is a key factor in reducing AIx in subjects with insulin resistance. Waist 
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circumference was not identified as an independent determinant when included instead of 
body weight in regression Model 4 (P=0.466). The association of FFA with AIx might be 
independent of adiposity. Serum FFA level also showed an inverse and independent 
association with central SBP after adjustment for brachial SBP (Model 5).  
FFA was a positive determinant for arterial tone when assessed via baPWV (Model 
6). However, the associations of FFA with AIx (Model 4), as well as central pressure (Model 
1, 2, and 5), were independent of baPWV, suggesting that changes in reflection magnitude 
rather than transit time of the reflection pressure wave might be involved in the paradoxical 
relationship between higher FFA and better central hemodynamic profiles. 
These findings were supported in the analysis using the replication panel 
irrespective of potential differences in fasting status, and no marked sex differences were 
found in any regression model (Table S3). When MBP was adjusted in the regression models 
instead of SBP, no marked changes were observed in the regression coefficients of FFA, as 
follows: Model 2 (PP amplification), β=0.030, P<0.001; Model 4 (AIx), β=-0.115, P<0.001; 
Model 5 (cSBP), β=-0.016, P<0.001; and Model 6 (baPWV), β=0.073, P<0.001. Further, the 
association of FFA with central hemodynamic parameter was independent of glycemic 
control levels assessed by HbA1c: HbA1c-adjusted regression coefficients of FFA; Model 2, 
β=0.022, P<0.001; Model 4, β=-0.123, P<0.001; Model 5, β=-0.044, P<0.001; and Model 6, 
β=0.069, P<0.001.  
 
DISCUSSION 
In the present study, we clarified that elevated serum FFA levels were strongly associated 
with increased PP amplification and decreased AIx, which represents relatively low central 
10 
 
BP, in a large-scale general population sample. To our knowledge, this is the first report of a 
favorable association of FFA with central BP and arterial waveform, which suggests the 
importance of insulin signaling as a modulator of central hemodynamics. Reduced magnitude 
of the reflection pressure wave might be involved in this paradoxical relationship. 
 Insulin resistance and diabetic status have been shown to be favorably associated 
with AIx and central BP in observational studies in patients with diabetes [22, 23] and general 
populations [9, 13], as well as in an experimental study using a euglycemic insulin clamp 
technique [24]. We also reported that not only increased insulin resistance but also reduced 
insulin sensitivity assessed by an oral glucose tolerance test were factors that modulate the 
arterial waveform and reduce central BP [12]. In the present study, however, serum FFA was 
a more prominent determinant of AIx than insulin. FFA initiates insulin resistance via 
upstream inhibition of insulin signaling in target cells, while increased plasma insulin levels 
or hyperinsulinemia are secondary responses to compensate for reduced glucose uptake under 
conditions of insulin resistance. The phase difference in the roles of FFA and insulin may 
explain the stronger association of FFA with AIx. 
 In stiffer arteries, the stiffness gradient from aorta to resistant artery was 
progressively dissipated. Decreased stiffness gradient reduces partial reflection of the forward 
pressure wave and increases transmission of the pulsatile energy into peripheral 
microcirculation, which reduces the magnitude of reflection [14]. Chirinos et al. recently 
observed selective stiffening of the aorta, but not more distal arteries, in patients with type 2 
diabetes and suggested that this selective stiffening was the underlying mechanism for the 
paradoxical observation of a lower reflection magnitude in subjects with type 2 diabetes [13]. 
Odaira et al. also reported that the contribution of the wave reflection to central 
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hemodynamics might be reduced in subjects with relatively stiff arteries [25]. As baPWV and 
AIx was inversely associated with FFA quartile, i.e. faster baPWV and lower AIx in higher 
FFA quartiles, our findings support the “pulsatile energy” hypothesis.  
 FFA plays a key role in the initiation of insulin resistance by inhibiting glucose 
uptake of target cells [15]. Given the importance of endothelium-derived NO in vascular 
relaxation shown in an animal model of hypertension [26], the decreased NO production at 
the endothelium and subsequent endothelial dysfunction are concomitant mechanisms for the 
development of insulin resistance via FFA [15]. As our study participants were an apparently 
healthy general population without severe insulin resistance, reduced endothelial NO 
production might be a principal factor in the increased aortic tone and consequently larger 
pulsatile energy in subjects with higher FFA. Insulin increases aortic tone by activating the 
sympathetic nervous system under the condition of insulin resistance. However, given the 
weak relationship between serum FFA and insulin levels, the involvement of insulin-mediated 
sympathetic activation might be independent of the effect of FFA. This is supported by the 
results of our regression analysis that show the insulin-independent association of FFA with 
baPWV.  
We also investigated associations between plasma lipid parameters and PP 
amplification, but no remarkable relationships were observed after adjustment for basic 
covariates. These results further emphasize the importance of serum FFA, but not lipid profile, 
as a factor involved in central hemodynamics. A previous study in Australia [27] reported that 
obesity, particularly visceral adiposity, was significantly associated with smaller AIx. As 
serum FFA is mostly released from enlarged and stressed adipose tissue [28], FFA might be a 
confounding factor in the inverse association between visceral adiposity and smaller AIx. No 
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association between waist circumference and AIx was observed in the present study, which 
supports our hypothesis. 
The maximum difference in PP amplification among all FFA quartiles was 
approximately 2.5 mmHg. This BP difference was somewhat larger than that observed in our 
previous reports of the association of smoking intensity [29] and insulin sensitivity [12]. The 
combination of FFA quartile and type 2 diabetes status further increased the maximum PP 
difference to 4.9 mmHg. A previous clinical study, the CAFE study [8], clearly indicated that 
even a 3-mmHg difference between brachial and central SBP was associated with improved 
cardiovascular outcomes. Further, several studies have shown that an increase in central SBP 
of only 1 mmHg has a substantial impact on large arterial remodeling [30] and silent cerebral 
damage [31]. Our findings therefore emphasize the importance of measuring serum FFA 
levels as a potential factor that modulates central hemodynamics, and of measuring central BP 
in epidemiological and clinical settings. 
Several limitations to the present study warrant mention. First, we did not directly 
measure transit time and magnitude of reflection pressure wave. As transit time largely 
correlate with baPWV, we deduced from results of the regression analysis that reduced 
magnitude rather than delayed arrival of reflection pressure wave might be involved in the 
paradoxical relationship between FFA and better central hemodynamic profiles. More 
detailed waveform analysis would be needed to obtain conclusive evidence. Second, as this 
was a cross-sectional study, a longitudinal study is required to confirm the prognostic 
significance of central SBP differences arising from differences in serum FFA levels. Third, 
no information on the class of antihypertensive drugs was available for the Nagahama cohort 
sample, though beta-blockers and vasodilators have substantial class-effects on central BP 
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that are well documented [4-8]. Given that the associations of FFA quartile with AIx and PPa 
were independent of antihypertensive medication, our results might be non-differential and 
independent of the class-effects of antihypertensive drugs.  
 
PERSPECTIVES 
In conclusion, we found that serum FFA level is an important factor influencing central 
hemodynamics. Our results might help identify the as yet unidentified mechanisms behind the 
favorable effects of insulin resistance and type 2 diabetes on the central hemodynamic profile. 
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NOVELTY AND SIGNIFICANCE 
What is new? 
! Elevated serum free fatty acid levels were strongly associated with reduced magnitude of 
arterial reflection pressure wave and relatively low central blood pressure. 
! Central pressure differs by approximately 4.9 mmHg due to serum FFA levels and 
diabetic status. 
  
What is relevant? 
Insulin resistance and diabetic status have been shown to be favorably associated with arterial 
waveform and central blood pressure. Serum free fatty acid was a more prominent 
determinant of arterial waveform than insulin. 
 
Summary 
Serum FFA was a factor that was favorably associated with central hemodynamics. A 
favorable association of FFA with central BP and arterial waveform suggests the importance 







Figure 1. Histogram of serum FFA level (study panel).  
Serum FFA level was significantly higher in female participants than in males (ANOVA 
P<0.001). 
 
Figure 2. Association of FFA quartile with central hemodynamic parameters (study 
panel).  
Numbers of study participants in each subgroup are shown in the column. Statistical 
significance was assessed by analysis of variance. A, B and C, PP amplification; D, 




Table 1. Clinical characteristics of study subjects 
  Study panel Replication panel 
  (4,322) (5,071) 
Age (years)  53±13 53±13 
Sex (male %)  31.6 32.9 
Body height (cm)  160.1±8.4 159.9±8.5 
Body weight (kg)  57.0±10.9 57.3±10.9 
Body mass index (kg/m2)  22.1±3.2 22.4±3.3 
Waist circumference (cm)*  79.8±9.8 80.4±9.3 
Medication (%) Hypertension 15.6 16.1 
 Hyperglycemia 2.4 2.4 
 Dyslipidemia 11.5 10.9 
Brachial SBP (mmHg)  123±18 124±18 
Central SBP (mmHg)  114±19 114±18 
DBP (mmHg)  76±11 76±11 
PP amplification (mmHg)  9±6 10±6 
Radial AIx (%)  81.6±13.4 79.8±13.4 
Heart rate (beats/min)  69±10 70±10 
baPWV (cm/sec)  1,261±231 1,262±227 
Type 2 diabetes  4.0 3.6 
Glucose (mg/dl)  90±14 90±16 
HbA1c (%)  5.5±0.5 5.4±0.5 
Insulin (µU/ml)  5.0±3.1 5.7±6.1 
Total cholesterol (mg/dl)  207±34 207±35 
HDL cholesterol (mg/dl)  66±17 65±17 
LDL cholesterol (mg/dl)  123±31 123±31 
Triglyceride (mg/dl)  91±58 103±68 
FFA (mEq/l)  0.69±0.24 0.78±0.31 
Values are mean ± standard deviation. The study panel consisted of individuals whose fasting 
blood specimens (>11 h) were available, and the replication panel consisted of individuals 
whose peripheral blood samples were drawn within 10 h of their last meal. *Data available for 
4,320 (study panel) and 5,069 (replication panel) subjects. Type 2 diabetes was defined as one 
or more of: fasting plasma glucose ≥126 mg/dl, occasional plasma glucose ≥200 mg/dl, 
HbA1c ≥6.5%, or taking oral antihyperglycemic drugs. AIx, augmentation index; baPWV, 
brachial-to-ankle pulse wave velocity; FFA, free fatty acid
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Table 2. Differences in metabolic parameters among the quartile of PP amplification (study panel) 
 Q1 Q2 Q3 Q4 P 
Range (mmHg) Male <6.5 6.5 to 9.9 10.0 to 14.4 >=14.5 Crude Adjusted 
 Female <4.5 4.5 to 7.4  7.5 to 10.9 >=11.0   
No. of subjects (982) (1,143) (1,101) (1,096)   
Age (years old) 57±11 56±12 53±13 47±14 <0.001  
Body height (cm) 158.5±7.9 159.0±8.0 160.4±8.1 162.6±8.8 <0.001  
Body weight (kg) 55.6±9.7 56.7±10.2 57.0±10.6 58.7±12.4 <0.001  
Brachial SBP (mmHg) 125±19 122±17 122±18 123±19 0.006  
Heart rate (beats/min) 64±8 67±9 70±10 74±11 <0.001  
Glucose (mg/dl) 90±13 90±11 91±16 91±14 0.026 <0.001 
Insulin (µU/ml) 4.6±2.8 5.0±2.9 5.0±2.9 5.5±3.5 <0.001 <0.001 
HOMA-IR 1.04±0.70 1.13±0.74 1.16±0.77 1.26±1.00 <0.001 <0.001 
HbA1c (%) 5.5±0.4 5.5±0.4 5.5±0.6 5.3±0.6 0.294 0.006 
Total cholesterol (mg/dl) 210±33 208±33 207±34 202±36 <0.001 0.362 
HDL cholesterol (mg/dl) 66±17 65±16 66±17 66±17 0.149 0.070 
LDL cholesterol (mg/dl) 126±30 125±30 123±31 119±32 <0.001 0.022 
Triglyceride (mg/dl) 91±51 93±57 90±53 90±69 0.618 0.337 
FFA (mEq/l) 0.63±0.23 0.68±0.23 0.71±0.24 0.74±0.25 <0.001 <0.001 
Values are mean ± standard deviation. Study subjects were divided into quartile by PP amplification within sex and then combined to avoid 
potential sex differences. Statistical significance was assessed by analysis of variance (crude model). P-values adjusted for age, sex, body height, 
body weight, and use of antihyperglycemic or lipid level-lowering drugs were obtained by linear regression analyses (adjusted model). 
HOMA-IR, homeostasis model assessment of insulin resistance; FFA, free fatty acid 
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Table 3. Multiple linear regression analysis for central hemodynamic parameters 
  PP amplification  AIx Central SBP baPWV 
  Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
Study panel 
(n=4,322) 



























 AIx (%)   
-1.004 
(<0.001)     











        
Replication panel 
(n=5,071) 



























 AIx (%)   
-1.003 
(<0.001)   
  











Values are standardized regression coefficients (β). P-values are shown in parenthesis. Adjusted factors were as follows: age, sex, body height, 
body weight, taking medication for hypertension or dyslipidemia, SBP, heart rate, total cholesterol, and baPWV. In regression Model 6, heart rate 
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Table S1. Correlation coefficient for serum FFA levels (study panel) 
 r P 
Age (years old) 0.087 <0.001 
Body mass index (kg/m2) -0.084 <0.001 
Brachial SBP (mmHg) 0.057 0.002 
Central SBP (mmHg) 0.018 0.243 
DBP (mmHg) 0.009 0.547 
Glucose (mg/dl) 0.016 0.295 
Insulin (µU/ml) -0.023 0.125 
HOMA-IR -0.010 0.503 
Total cholesterol (mg/dl) 0.085 <0.001 
HDL cholesterol (mg/dl) 0.190 <0.001 
LDL cholesterol (mg/dl) -0.004 0.807 
Triglyceride (mg/dl) -0.034 0.027 
HOMA-IR, homeostasis model assessment of insulin resistance. 
 
Table S2. Differences in metabolic parameters among the FFA quartile (study panel) 
 Q1 Q2 Q3 Q4 P 
Range (mEq/l) Male <0.45 0.45 to 0.57 0.58 to 0.72 >=0.73 Crude Adjusted 
 Female <0.56 0.56 to 0.69 0.70 to 0.86 >=0.87   
No. of subjects (1,042) (1,069) (1,103) (1,108)   
Age (years old) 50±13 53±13 54±13 55±14 <0.001  
Body height (cm) 161.1±8.5 160.5±8.2 159.9±8.3 159.2±8.3 <0.001  
Body weight (kg) 57.4±10.0 57.8±11.2 57.1±10.9 55.8±11.2 <0.001  
Heart rate (beats/min) 66±9 68±10 70±10 72±11 <0.001  
Glucose (mg/dl) 88±10 91±12 91±14 92±16 <0.001 <0.001 
Insulin (µU/ml) 5.0±3.0 5.1±3.0 5.2±3.2 4.9±3.0 0.306 0.053 
HOMA-IR 1.10±0.74 1.16±0.79 1.19±0.84 1.15±0.88 0.081 0.004 
HbA1c (%) 5.4±0.4 5.5±0.4 5.5±0.5 5.5±0.7 <0.001 0.005 
Total cholesterol (mg/dl) 203±33 206±33 208±34 211±35 <0.001 <0.001 
HDL cholesterol (mg/dl) 64±16 64±17 66±17 69±17 <0.001 <0.001 
LDL cholesterol (mg/dl) 122±30 124±31 123±30 124±32 0.437 0.866 
Triglyceride (mg/dl) 86±47 92±54 93±56 92±72 0.022 0.030 
Values are mean ± standard deviation. Study subjects were divided into FFA quartile within sex and then combined to avoid potential sex 
differences. Statistical significance was assessed by analysis of variance (crude model). P-values adjusted for age, sex, body height, body weight, 
and use of antihyperglycemic or lipid level-lowering drugs were obtained by linear regression analyses (adjusted model). HOMA-IR, 
homeostasis model assessment of insulin resistance; FFA, free fatty acid 
 
Table S3. Multiple linear regression analysis for central hemodynamic parameters by sex 
  PP amplification  AIx cSBP baPWV 
  Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
Male 
(n=3,031) 



























 AIx (%)   
-1.035 
(<0.001)     











        
Female 
(n=6,362) 



























 AIx (%)   
-1.013 
(<0.001)     











Values are standardized regression coefficient (β). P-values are shown in parenthesis. Adjusted factors were as follows; age, body height, body 
weight, taking medication for hypertension or dyslipidemia, SBP, heart rate, total cholesterol and baPWV. In the regression model 6, heart rate 




Figure S1 Mean adjusted central SBP levels by FFA quartile (Study panel) 
Adjusted factors were as follows: age, sex, body height, body weight, taking medication for 
hypertension or dyslipidemia, SBP, heart rate, total cholesterol, insulin, baPWV, and type 2 
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